Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Intangibles: 2014-2024

Historic Intangibles for ImmunityBio (IBRX) over the last 7 years, with Jun 2024 value amounting to $16.1 million.

  • ImmunityBio's Intangibles fell 15.45% to $16.1 million in Q2 2024 from the same period last year, while for Jun 2024 it was $16.1 million, marking a year-over-year decrease of 15.45%. This contributed to the annual value of $17.1 million for FY2023, which is 14.55% down from last year.
  • ImmunityBio's Intangibles amounted to $16.1 million in Q2 2024, which was down 3.10% from $16.6 million recorded in Q1 2024.
  • In the past 5 years, ImmunityBio's Intangibles registered a high of $22.3 million during Q1 2022, and its lowest value of $1.4 million during Q4 2021.
  • In the last 3 years, ImmunityBio's Intangibles had a median value of $19.2 million in 2023 and averaged $19.1 million.
  • Its Intangibles has fluctuated over the past 5 years, first skyrocketed by 1,454.17% in 2022, then dropped by 15.45% in 2024.
  • Over the past 5 years, ImmunityBio's Intangibles (Quarterly) stood at $1.5 million in 2020, then decreased by 2.94% to $1.4 million in 2021, then skyrocketed by 1,308.66% to $20.0 million in 2022, then dropped by 14.55% to $17.1 million in 2023, then fell by 15.45% to $16.1 million in 2024.
  • Its last three reported values are $16.1 million in Q2 2024, $16.6 million for Q1 2024, and $17.1 million during Q4 2023.